Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells

EGFR/HER2 are frequently expressed in MPM tissues, however, no studies have shown the clinical benefit of using EGFR/HER2-targeting drugs in patients with malignant pleural mesothelioma (MPM). It was reported that the tyrosine kinase inhibitor (TKI) lapatinib enhanced trastuzumab-mediated antibody-d...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncol Rep
Hlavní autoři: OKITA, RIKI, SHIMIZU, KATSUHIKO, NOJIMA, YUJI, YUKAWA, TAKURO, MAEDA, AI, SAISHO, SHINSUKE, NAKATA, MASAO
Médium: Artigo
Jazyk:Inglês
Vydáno: D.A. Spandidos 2015
Témata:
Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4722889/
https://ncbi.nlm.nih.gov/pubmed/26503698
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/or.2015.4314
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky